Published in Oncogene on April 29, 1999
Dovitinib(TKI258) in Patients With Castration-resistant Prostate Cancer | NCT01741116
A mouse model of hepatocellular carcinoma: ectopic expression of fibroblast growth factor 19 in skeletal muscle of transgenic mice. Am J Pathol (2002) 2.02
Altered fibroblast growth factor receptor 4 stability promotes prostate cancer progression. Neoplasia (2008) 1.26
Therapeutic targeting of the prostate cancer microenvironment. Nat Rev Urol (2010) 1.22
Evaluation of the fibroblast growth factor system as a potential target for therapy in human prostate cancer. Br J Cancer (2005) 1.20
Src family kinase/abl inhibitor dasatinib suppresses proliferation and enhances differentiation of osteoblasts. Oncogene (2010) 1.16
Cellular signaling by fibroblast growth factors (FGFs) and their receptors (FGFRs) in male reproduction. Endocr Rev (2008) 1.10
Growth factor signalling in prostatic growth: significance in tumour development and therapeutic targeting. Br J Pharmacol (2006) 1.04
FGF8 isoform b expression in human prostate cancer. Br J Cancer (2003) 1.01
Correlation of vascular endothelial growth factor expression with fibroblast growth factor-8 expression and clinico-pathologic parameters in human prostate cancer. Br J Cancer (2001) 0.99
Targeting fibroblast growth factor pathways in prostate cancer. Clin Cancer Res (2013) 0.98
Expression of bFGF/FGFR-1 and vascular proliferation related to clinicopathologic features and tumor progress in localized prostate cancer. Virchows Arch (2005) 0.97
FGFR4 Gly388Arg polymorphism contributes to prostate cancer development and progression: a meta-analysis of 2618 cases and 2305 controls. BMC Cancer (2011) 0.96
Zebrafish Hagoromo mutants up-regulate fgf8 postembryonically and develop neuroblastoma. Mol Cancer Res (2009) 0.96
Dissecting Major Signaling Pathways throughout the Development of Prostate Cancer. Prostate Cancer (2013) 0.94
Stromal activation associated with development of prostate cancer in prostate-targeted fibroblast growth factor 8b transgenic mice. Neoplasia (2010) 0.94
Association of FGFR4 genetic polymorphisms with prostate cancer risk and prognosis. Prostate Cancer Prostatic Dis (2008) 0.90
Role and expression of FRS2 and FRS3 in prostate cancer. BMC Cancer (2011) 0.89
Whole mount in situ hybridization detection of mRNAs using short LNA containing DNA oligonucleotide probes. RNA (2010) 0.89
A dominant-negative FGF1 mutant (the R50E mutant) suppresses tumorigenesis and angiogenesis. PLoS One (2013) 0.84
Association of transcript levels of 10 established or candidate-biomarker gene targets with cancerous versus non-cancerous prostate tissue from radical prostatectomy specimens. Clin Biochem (2013) 0.83
Fibroblast growth factor 8 is expressed at higher levels in lactating human breast and in breast cancer. Br J Cancer (2002) 0.82
Differential roles of fibroblast growth factor receptors (FGFR) 1, 2 and 3 in the regulation of S115 breast cancer cell growth. PLoS One (2012) 0.81
A long pentraxin-3-derived pentapeptide for the therapy of FGF8b-driven steroid hormone-regulated cancers. Oncotarget (2015) 0.80
Fast growth associated with aberrant vasculature and hypoxia in fibroblast growth factor 8b (FGF8b) over-expressing PC-3 prostate tumour xenografts. BMC Cancer (2010) 0.80
Fibroblast growth factors, old kids on the new block. Semin Cell Dev Biol (2016) 0.78
Current status and perspective of antiangiogenic therapy for cancer: urinary cancer. Int J Clin Oncol (2006) 0.77
Prostatic microenvironment in senescence: fibroblastic growth factors × hormonal imbalance. Histochem Cell Biol (2013) 0.75
Epidermal-growth-factor receptors in human bladder cancer: comparison of invasive and superficial tumours. Lancet (1985) 2.76
A prospective analysis of 1,930 patients with hematuria to evaluate current diagnostic practice. J Urol (2000) 2.73
Identification and isolation of human prostate epithelial stem cells based on alpha(2)beta(1)-integrin expression. J Cell Sci (2001) 2.64
Polygenic susceptibility to prostate and breast cancer: implications for personalised screening. Br J Cancer (2011) 2.28
Screening for prostate cancer in the UK. Seems to be creeping in by the back door. BMJ (2001) 2.22
Ambulatory urodynamics. Br J Urol (1996) 2.06
Epidermal growth factor receptors in non-small cell lung cancer. Br J Cancer (1987) 1.83
MEK5 overexpression is associated with metastatic prostate cancer, and stimulates proliferation, MMP-9 expression and invasion. Oncogene (2003) 1.83
Latest results from the UK trials evaluating prostate cancer screening and treatment: the CAP and ProtecT studies. Eur J Cancer (2010) 1.79
The management of men with acute urinary retention. National Prostatectomy Audit Steering Group. Br J Urol (1998) 1.76
Alternatively spliced mdm2 transcripts with loss of p53 binding domain sequences: transforming ability and frequent detection in human cancer. Nat Med (1996) 1.68
Tip60 is a nuclear hormone receptor coactivator. J Biol Chem (1999) 1.67
Written consent about sexual function in men undergoing transurethral prostatectomy. Br J Urol (1994) 1.65
Genetic divergence in the clonal evolution of breast cancer. Cancer Res (1996) 1.63
Suitability of PSA-detected localised prostate cancers for focal therapy: experience from the ProtecT study. Br J Cancer (2011) 1.62
Basal cells are progenitors of luminal cells in primary cultures of differentiating human prostatic epithelium. Prostate (1998) 1.61
Skin carriage of acinetobacters in Hong Kong. J Clin Microbiol (1999) 1.53
Computers in cardiovascular investigation. Br Heart J (1967) 1.53
Alpha 1-antichymotrypsin production in PSA-producing cells is common in prostate cancer but rare in benign prostatic hyperplasia. Urology (1994) 1.52
Bladder function in healthy volunteers: ambulatory monitoring and conventional urodynamic studies. Br J Urol (1994) 1.51
Clinical outcome and quality of life following enterocystoplasty for idiopathic detrusor instability and neurogenic bladder dysfunction. Br J Urol (1995) 1.50
Long-term outcome related to epidermal growth factor receptor status in bladder cancer. J Urol (1995) 1.49
Screening for bacteriuria in urological patients using reagent strips. Br J Urol (1992) 1.48
p53 and p53-regulated genes in bladder cancer. Br J Urol (1998) 1.46
Selective over-expression of fibroblast growth factor receptors 1 and 4 in clinical prostate cancer. J Pathol (2007) 1.46
Mucin gene expression in human urothelium and in intestinal segments transposed into the urinary tract. J Urol (2000) 1.45
Staging of prostate cancer using 3-dimensional transrectal ultrasound images: a pilot study. J Urol (1999) 1.43
Patient-Reported Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer. N Engl J Med (2016) 1.41
Expression of mutant p53, c-erbB-2 and the epidermal growth factor receptor in transitional cell carcinoma of the human urinary bladder. Br J Cancer (1991) 1.39
The effect of prostatectomy on symptom severity and quality of life. Br J Urol (1996) 1.39
Androgen receptor nuclear translocation is facilitated by the f-actin cross-linking protein filamin. Mol Endocrinol (2000) 1.38
Expression of RAC 3, a steroid hormone receptor co-activator in prostate cancer. Br J Cancer (2001) 1.37
Mean sojourn time, overdiagnosis, and reduction in advanced stage prostate cancer due to screening with PSA: implications of sojourn time on screening. Br J Cancer (2009) 1.36
Nuclear LYRIC/AEG-1 interacts with PLZF and relieves PLZF-mediated repression. Oncogene (2009) 1.33
Rectal, bladder and sexual function after mucosal proctectomy with and without a pelvic reservoir for colitis and polyposis. Br J Surg (1982) 1.33
Evaluation of epidermal growth factor receptors in bladder tumours. Br J Cancer (1987) 1.30
C-erbB-2 in bladder cancer: molecular biology, correlation with epidermal growth factor receptors and prognostic value. J Urol (1996) 1.30
The human cationic antimicrobial protein (hCAP-18) is expressed in the epithelium of human epididymis, is present in seminal plasma at high concentrations, and is attached to spermatozoa. Infect Immun (2000) 1.30
Identification and characterization of species of the family Bacteriodaceae by polyacrylamide gel electrophoresis. J Dent Res (1976) 1.28
A prospective randomized trial comparing transurethral resection of the prostate and laser therapy in men with chronic urinary retention: The CLasP study. J Urol (2000) 1.27
The RNA-binding and adaptor protein Sam68 modulates signal-dependent splicing and transcriptional activity of the androgen receptor. J Pathol (2008) 1.22
Statistical problems with 'optimal' thresholds in studies of new prognostic factors in urology. BJU Int (2000) 1.21
Evaluation of the fibroblast growth factor system as a potential target for therapy in human prostate cancer. Br J Cancer (2005) 1.20
β-Catenin activation synergizes with PTEN loss to cause bladder cancer formation. Oncogene (2010) 1.20
The case for samples of anonymized records from the 1991 census. J R Stat Soc Ser A Stat Soc (1991) 1.20
Genetic progression, histological grade, and allelic loss in ductal carcinoma in situ of the breast. Cancer Res (1996) 1.20
Comprehensive profiling and localisation of the matrix metalloproteinases in urothelial carcinoma. Br J Cancer (2006) 1.19
UHRF1 is a novel molecular marker for diagnosis and the prognosis of bladder cancer. Br J Cancer (2009) 1.18
Neuroendocrine differentiation in prostatic carcinoma during hormonal treatment. Urology (1998) 1.18
Transforming growth factor-beta1 up-regulates p15, p21 and p27 and blocks cell cycling in G1 in human prostate epithelium. J Endocrinol (1999) 1.17
Ras mutation cooperates with β-catenin activation to drive bladder tumourigenesis. Cell Death Dis (2011) 1.15
Nuclear accumulation of histone deacetylase 4 (HDAC4) coincides with the loss of androgen sensitivity in hormone refractory cancer of the prostate. Eur Urol (2004) 1.14
A multicenter analysis of the first experience with FK506 for induction and rescue therapy after pancreas transplantation. Transplantation (1996) 1.14
Lactate dehydrogenase-B is silenced by promoter hypermethylation in human prostate cancer. Oncogene (2006) 1.14
Aberrant expression of extracellular signal-regulated kinase 5 in human prostate cancer. Oncogene (2007) 1.13
Caveolin-1 expression is associated with high-grade bladder cancer. Urology (2001) 1.13
miR-205 negatively regulates the androgen receptor and is associated with adverse outcome of prostate cancer patients. Br J Cancer (2013) 1.13
Transurethral prostatic resection or laser therapy for men with acute urinary retention: the ClasP randomized trial. J Urol (2001) 1.12
Impact of prostate cancer testing: an evaluation of the emotional consequences of a negative biopsy result. Br J Cancer (2010) 1.12
Dacryocystorhinostomy in south west England. Eye (Lond) (1998) 1.11
High expression of tumour-associated trypsin inhibitor correlates with liver metastasis and poor prognosis in colorectal cancer. Br J Cancer (2009) 1.11
ERK5 signalling in prostate cancer promotes an invasive phenotype. Br J Cancer (2011) 1.10
Urinary diversion and bladder reconstruction/replacement using intestinal segments for intractable incontinence or following cystectomy. Cochrane Database Syst Rev (2003) 1.08
Expression of serotonin receptors and role of serotonin in human prostate cancer tissue and cell lines. Prostate (2004) 1.08
Transcutaneous electrical nerve stimulation and temporary S3 neuromodulation in idiopathic detrusor instability. J Urol (1996) 1.08
Induction of FGF receptor 2-IIIb expression and response to its ligands in epithelial ovarian cancer. Oncogene (2001) 1.07
A crossover randomized trial of transcutaneous electrical nerve stimulation and oxybutynin in patients with detrusor instability. J Urol (2001) 1.07
Tip60 is a co-activator specific for class I nuclear hormone receptors. J Biol Chem (2001) 1.07
The National Prostatectomy Audit: the clinical management of patients during hospital admission. Br J Urol (1995) 1.07
p53, c-erbB-2 and the epidermal growth factor receptor in the benign and malignant prostate. J Urol (1992) 1.06
Expression of the neutrophil-activating CXC chemokine ENA-78/CXCL5 by human eosinophils. Clin Exp Allergy (2003) 1.05
P53 and Ki-67 immunoreactivity in human prostate cancer and benign hyperplasia. Br J Urol (1992) 1.05
Immunohistochemical detection of the epidermal growth factor receptor in paraffin-embedded human tissues. J Pathol (1991) 1.05
Long-term follow-up of Anglian Germ Cell Cancer Group surveillance versus patients with Stage 1 nonseminoma treated with adjuvant chemotherapy. Urology (2004) 1.05
Characterization and quantitation of the epidermal growth factor receptor in invasive and superficial bladder tumors. Cancer Res (1989) 1.04
Cytokeratin 7: a useful adjunct in the diagnosis of chromophobe renal cell carcinoma. Histopathology (2002) 1.03
bcl-2 overexpression combined with p53 protein accumulation correlates with hormone-refractory prostate cancer. Br J Cancer (1996) 1.03
Systematic review and economic modelling of the relative clinical benefit and cost-effectiveness of laparoscopic surgery and robotic surgery for removal of the prostate in men with localised prostate cancer. Health Technol Assess (2012) 1.03
Cell adhesion molecules in bladder cancer: soluble serum E-cadherin correlates with predictors of recurrence. Br J Cancer (1996) 1.03
Epididymectomy is an effective treatment for scrotal pain after vasectomy. BJU Int (2000) 1.03
Surface localization of sacral foramina for neuromodulation of bladder function. An anatomical study. Eur Urol (1996) 1.02
Secretory leucocyte protease inhibitor in the male genital tract: PSA-induced proteolytic processing in human semen and tissue localization. J Androl (1995) 1.02
Androgens modulate autophagy and cell death via regulation of the endoplasmic reticulum chaperone glucose-regulated protein 78/BiP in prostate cancer cells. Cell Death Dis (2010) 1.02
Peroxisome proliferator-activated receptor alpha is an androgen-responsive gene in human prostate and is highly expressed in prostatic adenocarcinoma. Clin Cancer Res (2000) 1.02
The expression of waf-1, p53 and bcl-2 in prostatic adenocarcinoma. Br J Urol (1997) 1.02
FGF8 isoform b expression in human prostate cancer. Br J Cancer (2003) 1.01